| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
LOCUS for Homocysteine and Related Vitamins, University of Bergen, Armauer Hansens Hus, N-5021 Bergen, Norway.
a Author for correspondence. Fax 47-55-974605; e-mail steinar.hustad{at}farm.uib.no
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Methods: The study had a cross-sectional design and included 423 healthy blood donors, ages 19–69 years. We determined plasma tHcy, serum folate, serum cobalamin, serum creatinine, and MTHFR C677T genotype. In addition, we measured riboflavin and its two coenzyme forms, flavin mononucleotide and flavin adenine dinucleotide, in EDTA plasma by capillary electrophoresis and laser-induced fluorescence detection.
Results: Riboflavin determined tHcy independently in a multiple linear regression model with adjustment for sex, age, folate, cobalamin, creatinine, and MTHFR genotype (P = 0.008). tHcy was 1.4 µmol/L higher in the lowest compared with the highest riboflavin quartile. The riboflavin-tHcy relationship was modified by genotype (P = 0.004) and was essentially confined to subjects with the C677T transition of the MTHFR gene.
Conclusions: Plasma riboflavin is an independent determinant of plasma tHcy. Studies on deficient populations are needed to evaluate the utility of riboflavin supplementation in hyperhomocysteinemia.
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Homocysteine is an important intermediate in one-carbon metabolism. Intracellular homocysteine is either converted to cysteine via the vitamin B6-dependent transsulfuration pathway or is remethylated to methionine (4). In most tissues, the latter reaction is catalyzed by the ubiquitous enzyme methionine synthase (EC 2.1.1.13), which requires cobalamin as a cofactor and 5-methyltetrahydrofolate as a methyl donor (4). This explains why folate and cobalamin are major determinants of plasma tHcy (5).
The formation of 5-methyltetrahydrofolate is catalyzed by the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR; EC 1.7.99.5) (4). The commonly occurring C677T polymorphism of the MTHFR gene confers reduced enzyme activity and is associated with a moderate increase in tHcy (6), particularly in subjects with impaired folate status (7)(8)(9)(10).
Riboflavin is the precursor of flavin mononucleotide (FMN) and FAD (11), which serve as cofactors for enzymes involved in the metabolism of vitamin B6, folate, and cobalamin (12)(13)(14)(15)(16). FMN serves as a cofactor for pyridoxine-5'-phosphate oxidase (EC 1.4.3.5), which is important for the formation of the active form of vitamin B6, pyridoxal-5'-phosphate (12)(14), whereas FAD is a cofactor for MTHFR (13)(16). Both flavin coenzymes are involved in cobalamin metabolism (12) and serve as cofactors for methionine synthase reductase (EC 2.1.1.135) (15). The role of flavoenzymes in the metabolism of several B vitamins points to the possibility that riboflavin status may influence homocysteine metabolism and thereby plasma tHcy concentration.
Riboflavin status in humans is usually assessed by the erythrocyte glutathione reductase activity coefficient (17)(18). We recently developed a capillary electrophoresis method for the determination of riboflavin, FMN, and FAD in plasma (19), and we used this assay to determine the possible relationship between riboflavin status and plasma tHcy in 423 blood donors. Folate and MTHFR status were also determined because MTHFR is a FAD-dependent enzyme with major effects on intracellular folate distribution (20).
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
) in the study. The subjects were predominantly Caucasian and
were recruited at the Blood Bank of Haukeland University Hospital,
Bergen, Norway. No medication was allowed except inhaled drugs and
hormonal substitution. The subjects were not fasting.
|
The procedures followed were in accordance with the Helsinki Declaration, and all participants gave informed consent.
Blood sampling
Blood samples were collected into Venoject tubes with EDTA (Terumo
Europe). The samples were immediately put on ice, and plasma was
obtained by centrifugation within 30 min. Venoject plain silicon-coated
tubes (Terumo Europe) were centrifuged within 1 h after sampling
to obtain serum. EDTA plasma and serum were stored at -70 °C until
analysis.
Biochemical analyses
Plasma tHcy was analyzed by HPLC and fluorescence detection
(21).
Riboflavin, FMN, and FAD were determined in EDTA plasma by a modification of the method described by Hustad et al. (19). A plasma volume of 25 µL was used for the analysis. Trichloroacetic acid (75 µL of a 100 g/L solution) containing 15 nmol/L isoriboflavin was added to the samples, and 75 µL of the supernatant was neutralized by the addition of 24 µL of 2 mol/L K2HPO4. The neutralized trichloroacetic acid-treated plasma was subjected to solid-phase extraction using C18 columns as described in the original publication (19), except that doubly distilled water was used instead of phosphate buffer. The eluate was lyophilized overnight (Lyovac GT2; Leybold-Heraeus), and the analytes were then dissolved in 25 µL of water. The vitamers were separated by capillary electrophoresis on a Beckman P/ACE System 2210 (Beckman Instruments) and detected by laser-induced fluorescence.
Serum folate was determined by a Lactobacillus casei microbiological assay (22) and serum cobalamin by a L. leichmannii microbiological assay (23). Both the folate and cobalamin assays were adapted to a microtiter plate formate and carried out by a robotic workstation (Microlab AT plus 2; Hamilton Bonaduz).
Serum creatinine was determined using the alkaline picrate method for the CHEM 1 system (Technicon).
MTHFR C677T genotyping was performed according to the method described by Ulvik et al. (24). Whole blood (1 µL) was added directly to the reaction vessel. The blood was overlaid with 50 µL of PCR master mixture and subjected to 33 thermocycles. The allele-specific PCR products were analyzed by multiple-injection capillary electrophoresis.
Serum thyrotropin was measured by a fluoroimmunoassay (autoDELFIA; Wallac Oy).
Statistical methods
Medians with 5th and 95th percentiles and geometric means with
95% confidence intervals were used for descriptive statistics. Means
were compared using the Student t-test and one-way ANOVA.
Multiple linear regression models were used to assess the simultaneous
relationship between the various predictors and tHcy. The independent
variables were represented in the model as indicator variables denoting
membership to one of four categories for age, riboflavin, folate,
cobalamin, and creatinine. Thus, the regression coefficients estimated
the difference in mean tHcy between the reference category and the
other categories for each factor. tHcy concentrations across categories
of each factor were tested for linear trend.
We investigated the possible interaction between plasma riboflavin and MTHFR C677T genotype (coded as 0 for CC, 1 for CT, and 2 for TT) by including a product term between the two variables in a multiple linear regression model with tHcy as the dependent variable, retaining riboflavin and genotype as independent variables in the model. Similarly, we investigated the possible interaction between plasma riboflavin and serum folate.
To further investigate the interaction between plasma riboflavin and MTHFR C677T genotype, we studied the relationship between riboflavin and tHcy in the CC and the CT/TT groups separately. For these analyses, we used generalized additive gaussian regression with adjustment for sex, age, folate, cobalamin, and creatinine. This method gives a graphical presentation of the relationship between riboflavin and tHcy. The estimated adjusted difference in tHcy between any two riboflavin concentrations can be read from the graph. Because of the low number of subjects with the TT genotype, CT and TT individuals were combined into one group. We also investigated the riboflavin-tHcy relationship at serum folate concentrations above and below median.
SPSS, Ver. 9.0 for Windows (SPSS Inc.), was used for all statistical analyses except generalized additive gaussian regression, which was performed by S-PLUS 2000 for Windows (MathSoft). All tests were 2-tailed, and P <0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
)
with a mean age of 42 years (range, 19–69 years). Men had higher
median plasma tHcy (9.7 µmol/L) than women (8.0 µmol/L). Plasma
FAD and serum cobalamin concentrations were higher in men than in
women, whereas plasma riboflavin, plasma FMN, and serum folate
concentrations were not different between genders (Table 1
)
(19). All subjects had folate and cobalamin concentrations
above the lower reference limits, except one subject with serum folate
<4.5 nmol/L and one subject with serum cobalamin <150 pmol/L.
tHcy, riboflavin, and FMN (19) showed a skewed distribution,
whereas FAD, folate, cobalamin, creatinine, and age were more
symmetrically distributed (Table 1
).
The MTHFR C677T genotype frequencies for CC, CT, and TT were
48%, 43%, and 9%, respectively. tHcy and folate concentrations were
significantly related to genotype, and subjects with the TT genotype
had higher tHcy and lower folate than subjects with the CC and CT
genotypes (Table 2
). Concentrations of riboflavin, FMN, FAD, and cobalamin were
not related to MTHFR status (Table 2
).
|
We measured thyrotropin in 42 subjects with riboflavin in the lowest decile to investigate the possibility of subclinical hypothyroidism. Their mean value was 1.5 mIU/L (range, 0.4–4.7 mIU/L), which is within the reference range (0.3–5.0 mIU/L) of our laboratory.
Bivariate correlations
Plasma riboflavin, serum folate, serum creatinine, and age
correlated significantly with tHcy (Table 3
). Spearman correlation coefficients for the riboflavin-tHcy
relationship were calculated separately for the CC, CT, and TT
genotypes and were -0.05 (P = 0.5), -0.13
(P = 0.07), and -0.31 (P = 0.07),
respectively. When the CT and the TT groups were combined, the
correlation coefficient was -0.18 (P = 0.009).
|
There was a positive correlation between riboflavin and cobalamin,
whereas the correlation between riboflavin and folate was not
significant. Compared with riboflavin, FMN showed a weaker correlation
to tHcy and a correlation similar to cobalamin. In contrast, FAD was
positively correlated to tHcy as well as age and creatinine (Table 3
).
Multiple regression analyses
Plasma riboflavin, serum folate, serum cobalamin, serum
creatinine, MTHFR C677T genotype, and age were associated
with plasma tHcy in a multiple linear regression model (Table 4
). Riboflavin was significantly inversely related to tHcy after
adjustment for sex and age and after additional adjustment for folate,
cobalamin, creatinine, and genotype. Plasma tHcy was 1.4 µmol/L
higher in the lowest compared with the highest riboflavin quartile
(Table 4
). When subjects with the TT genotype were excluded from the
analysis, the corresponding tHcy difference was 0.8 µmol/L
(P = 0.02). Thus, the magnitude of the effect was
similar to that observed for cobalamin but less than for folate (Table 4
).
|
We used generalized additive gaussian regression to estimate the
adjusted dose–response curve between plasma riboflavin and plasma tHcy
in the CC and CT/TT groups. We found a significant inverse relationship
between plasma riboflavin and tHcy in the CT/TT group, but not in the
CC group (Fig. 1
). This was further investigated in four groups defined by MTHFR
genotype and serum folate concentrations above and below median. The
riboflavin-tHcy association was present both at high and low folate in
the CT/TT but not the CC group (Fig. 1
). This modification of the
riboflavin-tHcy relationship by MTHFR status was
statistically significant (P = 0.004; Table 4
, model
2). No corresponding effect of folate status on the riboflavin-tHcy
relationship was detected (Table 4
, model 3).
|
We found no significant association between plasma concentrations of flavin coenzymes and tHcy. FMN was inversely related to tHcy in a multiple regression model, but the association failed to reach significance after adjustment for sex and age (P = 0.06) and after additional adjustment for folate, cobalamin, creatinine, and MTHFR C677T genotype (P = 0.3). No relationship was observed between plasma FAD and tHcy in a corresponding regression model with adjustment for age and creatinine (P = 0.9).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
and 4
). The association is essentially confined to subjects with the CT/TT
genotype of the MTHFR C677T polymorphism (Fig. 1
).
The study had a cross-sectional design and included 423 healthy male
and female blood donors, 19–69 years of age. Their nutritional status
was adequate as judged by blood vitamin concentrations (Table 1
). Only
3.8% of the subjects had tHcy concentrations >15 µmol/L, compared
with 9.3% in the Hordaland homocysteine cohort (25), and
this probably reflects a healthy life-style and adequate B-vitamin
status in our study population. The types and strengths of the
associations between tHcy and folate, cobalamin, creatinine,
MTHFR genotype, sex, and age (Tables 1–4
) were in agreement
with published data (26)(27). Thus, we have
demonstrated a riboflavin-tHcy relationship in a healthy population
that is not vitamin B-deficient. Conceivably, this relationship may be
even stronger in riboflavin-deficient subjects.
The inverse relationship between tHcy and plasma riboflavin remained
significant after adjustment for other tHcy predictors, including
folate (Table 4
). Because low folate is associated with high tHcy,
particularly in subjects with the TT genotype (Table 2
)
(7)(8)(9)(10), there might be residual confounding from folate
status. This possibility seems unlikely, however, because the
riboflavin-tHcy relationship was also observed in subjects with high
serum folate (Fig. 1
).
The association between riboflavin and tHcy is most likely mediated by
the MTHFR enzyme. This is supported by the observation that the
riboflavin effect is dependent on MTHFR genotype (Table 4
and Fig. 1
). Thus, riboflavin deficiency may reduce MTHFR activity,
which in turn decreases the availability of 5-methyltetrahydrofolate
(10)(20) and thereby homocysteine remethylation.
This idea is supported by the finding that MTHFR activity
(13)(28) and relative amounts of
5-methyltetrahydrofolate
(13)(28)(29) are reduced in the
liver of riboflavin-deficient rats.
The recent finding of Guenther et al. (16) provides an
explanation for the increased tHcy responsiveness to low riboflavin in
subjects with the CT/TT genotype (Fig. 1
). The authors showed that the
A177V mutation of bacterial MTHFR, which is homologous to the A222V
(C677T) substitution in human MTHFR, was associated with an enhanced
FAD dissociation rate (16). Thus, subjects with the T allele
may require higher concentrations of FAD for maximal catalytic
activity.
We suggest that the riboflavin-tHcy relationship is mediated by the FAD-dependent enzyme MTHFR. This raises the question of why plasma riboflavin, but not FAD, is associated with tHcy. Published data indicate that plasma/serum concentrations of riboflavin may reflect tissue riboflavin status better than FAD (30)(31). In a group of riboflavin-deficient men maintained on restricted riboflavin intake for several months, the sum of plasma riboflavin and plasma FMN was lower than in the control group, whereas plasma FAD was not significantly different (31). In riboflavin-deficient rats whose growth was improved by successive addition of dietary riboflavin, serum riboflavin increased proportionally much more than serum FAD during supplementation (30). Furthermore, in tissues of riboflavin-deficient rats, riboflavin decreased to very low concentrations (32)(33)(34) with partial preservation of flavin coenzymes, in particular FAD (33)(34)(35).
The distribution of riboflavin, FMN, and FAD in tissues is probably under strict metabolic control (33)(34)(36). The existence of such regulatory processes is indicated by a selective preservation of some flavoenzyme-dependent metabolic pathways in riboflavin deficiency (13)(34). Notably, in riboflavin-deficient rats, hepatic MTHFR activity is markedly reduced, demonstrating that this enzyme is sensitive to riboflavin deficiency (13)(28). Our data suggest that this response may be modulated by the C677T polymorphism in humans. Reduced MTHFR activity may in turn alter folate distribution by directing folate species toward the synthesis of purines and pyrimidines at the expense of 5-methyltetrahydrofolate synthesis. We hypothesize that this mechanism may secure DNA and RNA synthesis of proliferating cells in folate deficiency (13)(28).
In conclusion, plasma riboflavin is an independent predictor of tHcy. Our results indicate that riboflavin status may affect tissue distribution and economy of reduced folate by modifying MTHFR activity, particularly in subjects with the C677T transition. Studies on riboflavin-deficient populations are needed to evaluate the utility of riboflavin supplementation in hyperhomocysteinemia.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
40 µmol/liter)—the Hordaland Homocysteine Study. J Clin Investig 1996;98:2174-2183.
[Web of Science][Medline]
[Order article via Infotrieve]
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  L. Hoey, H. McNulty, and J. Strain Studies of biomarker responses to intervention with riboflavin: a systematic review Am. J. Clinical Nutrition, June 1, 2009; 89(6): 1960S - 1980S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ganji and M. R. Kafai Demographic, Lifestyle, and Health Characteristics and Serum B Vitamin Status Are Determinants of Plasma Total Homocysteine Concentration in the Post-Folic Acid Fortification Period, 1999-2004 J. Nutr., February 1, 2009; 139(2): 345 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. DeVos, A. Chanson, Z. Liu, E. D Ciappio, L. D Parnell, J. B Mason, K. L Tucker, and J. W Crott Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations Am. J. Clinical Nutrition, October 1, 2008; 88(4): 1149 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wallace, M. P Bonham, J. Strain, E. M Duffy, P. J Robson, M. Ward, H. McNulty, P. W Davidson, G. J Myers, C. F Shamlaye, et al. Homocysteine concentration, related B vitamins, and betaine in pregnant women recruited to the Seychelles Child Development Study Am. J. Clinical Nutrition, February 1, 2008; 87(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S McCully Homocysteine, vitamins, and vascular disease prevention Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1563S - 1568S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Midttun, S. Hustad, J. Schneede, S. E Vollset, and P. M Ueland Plasma vitamin B-6 forms and their relation to transsulfuration metabolites in a large, population-based study Am. J. Clinical Nutrition, July 1, 2007; 86(1): 131 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. I. Holm, S. Hustad, P. M. Ueland, S. E. Vollset, T. Grotmol, and J. Schneede Modulation of the Homocysteine-Betaine Relationship by Methylenetetrahydrofolate Reductase 677 C->T Genotypes and B-Vitamin Status in a Large-Scale Epidemiological Study J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1535 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. McLean, L. H. Allen, C. G. Neumann, J. M. Peerson, J. H. Siekmann, S. P. Murphy, N. O. Bwibo, and M. W. Demment Low Plasma Vitamin B-12 in Kenyan School Children Is Highly Prevalent and Improved by Supplemental Animal Source Foods J. Nutr., March 1, 2007; 137(3): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. McNulty, L. R. C. Dowey, J.J. Strain, A. Dunne, M. Ward, A. M. Molloy, L. B. McAnena, J. P. Hughes, M. Hannon-Fletcher, and J. M. Scott Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C->T Polymorphism Circulation, January 3, 2006; 113(1): 74 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Midttun, S. Hustad, E. Solheim, J. Schneede, and P. M. Ueland Multianalyte Quantification of Vitamin B6 and B2 Species in the Nanomolar Range in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., July 1, 2005; 51(7): 1206 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van den Donk, B. Buijsse, S. W. van den Berg, M. C. Ocke, J. L. Harryvan, F. M. Nagengast, F. J. Kok, and E. Kampman Dietary Intake of Folate and Riboflavin, MTHFR C677T Genotype, and Colorectal Adenoma Risk: A Dutch Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1562 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hustad, B. G Nedrebo, P. M. Ueland, J. Schneede, S. E. Vollset, A. Ulvik, and E. A Lien Phenotypic expression of the methylenetetrahydrofolate reductase 677C->T polymorphism and flavin cofactor availability in thyroid dysfunction Am. J. Clinical Nutrition, October 1, 2004; 80(4): 1050 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Narayanan, J. McConnell, J. Little, L. Sharp, C. J. Piyathilake, H. Powers, G. Basten, and S. J. Duthie Associations between Two Common Variants C677T and A1298C in the Methylenetetrahydrofolate Reductase Gene and Measures of Folate Metabolism and DNA Stability (Strand Breaks, Misincorporated Uracil, and DNA Methylation Status) in Human Lymphocytes In vivo Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1436 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sharp and J. Little Polymorphisms in Genes Involved in Folate Metabolism and Colorectal Neoplasia: A HuGE Review Am. J. Epidemiol., March 1, 2004; 159(5): 423 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin, et al. Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion Clin. Chem., January 1, 2004; 50(1): 3 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kimura, K. Umegaki, M. Higuchi, P. Thomas, and M. Fenech Methylenetetrahydrofolate Reductase C677T Polymorphism, Folic Acid and Riboflavin Are Important Determinants of Genome Stability in Cultured Human Lymphocytes J. Nutr., January 1, 2004; 134(1): 48 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Spotila, P. F. Jacques, P. B. Berger, K. V. Ballman, R. C. Ellison, and R. Rozen Age Dependence of the Influence of Methylenetetrahydrofolate Reductase Genotype on Plasma Homocysteine Level Am. J. Epidemiol., November 1, 2003; 158(9): 871 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wolters, S. Hermann, and A. Hahn B vitamin status and concentrations of homocysteine and methylmalonic acid in elderly German women Am. J. Clinical Nutrition, October 1, 2003; 78(4): 765 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J Powers Riboflavin (vitamin B-2) and health Am. J. Clinical Nutrition, June 1, 2003; 77(6): 1352 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Guinotte, M. G. Burns, J. A. Axume, H. Hata, T. F. Urrutia, A. Alamilla, D. McCabe, A. Singgih, E. A. Cogger, and M. A. Caudill Methylenetetrahydrofolate Reductase 677C->T Variant Modulates Folate Status Response to Controlled Folate Intakes in Young Women J. Nutr., May 1, 2003; 133(5): 1272 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ganji and M. R Kafai Demographic, health, lifestyle, and blood vitamin determinants of serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey, 1988-1994 Am. J. Clinical Nutrition, April 1, 2003; 77(4): 826 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Robien and C. M. Ulrich 5,10-Methylenetetrahydrofolate Reductase Polymorphisms and Leukemia Risk: A HuGE Minireview Am. J. Epidemiol., April 1, 2003; 157(7): 571 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. de Bree, W. M. Verschuren, A.-L. Bjorke-Monsen, N. M. van der Put, S. G Heil, F. J. Trijbels, and H. J Blom Effect of the methylenetetrahydrofolate reductase 677C->T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample Am. J. Clinical Nutrition, March 1, 2003; 77(3): 687 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Mason Biomarkers of Nutrient Exposure and Status in One-Carbon (Methyl) Metabolism J. Nutr., March 1, 2003; 133(3): 941S - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Moat, P. A.L. Ashfield-Watt, H. J. Powers, R. G. Newcombe, and I. F.W. McDowell Effect of Riboflavin Status on the Homocysteine-lowering Effect of Folate in Relation to the MTHFR (C677T) Genotype Clin. Chem., February 1, 2003; 49(2): 295 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Meleady, P. M Ueland, H. Blom, A. S Whitehead, H. Refsum, L. E Daly, S. E. Vollset, C. Donohue, B. Giesendorf, I. M Graham, et al. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project Am. J. Clinical Nutrition, January 1, 2003; 77(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P Quinlivan and J. F Gregory III Effect of food fortification on folic acid intake in the United States Am. J. Clinical Nutrition, January 1, 2003; 77(1): 221 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hustad, M. C. McKinley, H. McNulty, J. Schneede, J.J. Strain, J. M. Scott, and P. M. Ueland Riboflavin, Flavin Mononucleotide, and Flavin Adenine Dinucleotide in Human Plasma and Erythrocytes at Baseline and after Low-Dose Riboflavin Supplementation Clin. Chem., September 1, 2002; 48(9): 1571 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rozen Methylenetetrahydrofolate reductase: a link between folate and riboflavin? Am. J. Clinical Nutrition, August 1, 2002; 76(2): 301 - 302. [Full Text] [PDF]
|
|
|
|
|
|
H. McNulty, M. C McKinley, B. Wilson, J. McPartlin, J. Strain, D. G Weir, and J. M Scott Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements Am. J. Clinical Nutrition, August 1, 2002; 76(2): 436 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Skoupy, M. Fodinger, M. Veitl, A. Perschl, H. Puttinger, C. Rohrer, K. Schindler, A. Vychytil, W. H. Horl, and G. Sunder-Plassmann Riboflavin Is a Determinant of Total Homocysteine Plasma Concentrations in End-Stage Renal Disease Patients J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1331 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N Ames, I. Elson-Schwab, and E. A Silver High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms Am. J. Clinical Nutrition, April 1, 2002; 75(4): 616 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-J. Hung, P.-C. Huang, S.-C. Lu, Y.-H. Li, H.-B. Huang, B.-F. Lin, S.-J. Chang, and H.-F. Chou Plasma Homocysteine Levels in Taiwanese Vegetarians Are Higher than Those of Omnivores J. Nutr., February 1, 2002; 132(2): 152 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Jacques, R. Kalmbach, P. J. Bagley, G. T. Russo, G. Rogers, P. W. F. Wilson, I. H. Rosenberg, and J. Selhub The Relationship between Riboflavin and Plasma Total Homocysteine in the Framingham Offspring Cohort Is Influenced by Folate Status and the C677T Transition in the Methylenetetrahydrofolate Reductase Gene J. Nutr., February 1, 2002; 132(2): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamada, Z. Chen, R. Rozen, and R. G. Matthews Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase PNAS, December 6, 2001; (2001) 261469998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Crott, S. T. Mashiyama, B. N. Ames, and M. Fenech The Effect of Folic Acid Deficiency and MTHFR C677T Polymorphism on Chromosome Damage in Human Lymphocytes in Vitro Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1089 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. McKinley, J.J. Strain, J. McPartlin, J. M. Scott, and H. McNulty Plasma Homocysteine Is Not Subject to Seasonal Variation Clin. Chem., August 1, 2001; 47(8): 1430 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Crott, S. T. Mashiyama, B. N. Ames, and M. F. Fenech Methylenetetrahydrofolate reductase C677T polymorphism does not alter folic acid deficiency-induced uracil incorporation into primary human lymphocyte DNA in vitro Carcinogenesis, July 1, 2001; 22(7): 1019 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Fokkema, J. M. Weijer, D.A. J. Dijck-Brouwer, J. J. van Doormaal, and F. A.J. Muskiet Influence of Vitamin-optimized Plasma Homocysteine Cutoff Values on the Prevalence of Hyperhomocysteinemia in Healthy Adults Clin. Chem., June 1, 2001; 47(6): 1001 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Herrmann, H. Schorr, K. Purschwitz, F. Rassoul, and V. Richter Total Homocysteine, Vitamin B12, and Total Antioxidant Status in Vegetarians Clin. Chem., June 1, 2001; 47(6): 1094 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Lien, S. Hustad, B. G. Nedrebø, O. Nygård, and P. M. Ueland Total Plasma Homocysteine in Hypo- and Hyperthyroidism: Covariations and Causality J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1846 - 1846. [Full Text]
|
|
|
|
|
|
E. Nurk, G. S. Tell, O. Nygård, H. Refsum, P. M. Ueland, and S. E. Vollset Plasma Total Homocysteine Is Influenced by Prandial Status in Humans: The Hordaland Homocysteine Study J. Nutr., April 1, 2001; 131(4): 1214 - 1216. [Abstract] [Full Text]
|
|
|
|
|
|
S. E. Vollset, H. Refsum, and P. M. Ueland Population determinants of homocysteine Am. J. Clinical Nutrition, March 1, 2001; 73(3): 499 - 500. [Full Text] [PDF]
|
|
|
|
|
|
P. F Jacques, A. G Bostom, P. W. Wilson, S. Rich, I. H Rosenberg, and J. Selhub Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort Am. J. Clinical Nutrition, March 1, 2001; 73(3): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamada, Z. Chen, R. Rozen, and R. G. Matthews Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase PNAS, December 18, 2001; 98(26): 14853 - 14858. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
